Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 9,650

Document Document Title
WO/2020/068657A1
Halogenated analogs of 5-aza-2'-deoxycytidine, such as halogenated analogs of 5-aza-4'-thio-2'-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated an...  
WO/2020/069424A1
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...  
WO/2020/056713A1
A method for preparing high-purity NAD, comprising: adjusting a pH value to 6.0-8.0, removing insoluble substances, heating to 35 ± 1°C, adding ethanol, cooling to 6 ± 0.5°C, crystallizing, filtering, heating a filtrate to 25-30°C, ...  
WO/2020/057546A1
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...  
WO/2020/054444A1
[Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the for...  
WO/2020/055753A1
The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or...  
WO/2020/051686A1
CD73 (also known as ecto-5 ' -nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...  
WO/2020/050411A1
The present invention provides a method for producing a glycoside compound represented by general formula (3), said glycoside compound enabling the synthesis of a desired compound (an amidite) with high purity. This method comprises a st...  
WO/2020/045628A1
The present invention addresses the problem of providing a nucleic acid analog, and a pharmaceutical composition, an anti-hepatitis virus agent and a preventive or therapeutic agent for a hepatitis virus-related disease each comprising a...  
WO/2020/047082A1
This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents fo...  
WO/2020/042729A1
Disclosed are a 6-disulfide-substituted-2'-deoxyguanosine compound and a preparation method therefor and a use thereof in an anti-tumor drug. Using 2'-deoxyguanosine as a structure mother nucleus, the present invention designs and synthe...  
WO/2020/041051A1
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.  
WO/2020/041050A1
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.  
WO/2020/037275A1
Disclosed is a compound of formula (I), wherein Q, U, T, A, a, b, c, and n are as defined herein. Also disclosed are methods of inhibiting ecto‑5'‑nucleotidase, inhibiting suppression of an antitumor immune response, inhibiting tumor...  
WO/2020/036199A1
The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-3 4,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,2 0,22,25,27-decaaza-34λ5,39λ5-diphosphaoctacyclo[28.6.4.13, 36.128,31.0...  
WO/2020/032152A1
Current synthesis methods for 4'-substituted nucleoside derivatives include a step in which stereoisomers are produced and therefore have problems such as decreased yield and complication of a refinement step. Thus, a synthesis method ha...  
WO/2020/033624A1
The present disclosure is directed to methods of treating a disease associated with pathogenic B cells comprising administering to a subject in need thereof an effective amount of an Adora2A (adenosine A2A receptor) agonist. The method m...  
WO/2020/031131A1
The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.  
WO/2020/029647A1
Provided in the present invention is a method for synthesizing a nucleoside compound and an intermediate thereof, wherein the method is carried out by introducing a protective group at position 6 of guanine ketocarbonyl, causing only 9 N...  
WO/2020/028682A1
The present invention relates to amino acid salts of nicotinic acid and nicotinamide and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: (I) wherein A, L, M1, M2,...  
WO/2020/026054A1
The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as ph...  
WO/2020/020208A1
The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and per...  
WO/2020/017085A1
The present invention pertains to: an alkoxyphenyl derivative with which oligonucleotides can by synthesized by a liquid-phase synthesis method easier and faster than conventional methods; a nucleoside protector and a nucleotide protecto...  
WO/2020/013712A1
Inhibitors of DNA methyltransferase 1 (an enzyme responsible for the maintenance of DNA CpG methylation marks in human cells) and their use as therapeutic agents against various cancers. The invention relates to compounds, pharmaceutical...  
WO/2020/010560A1
Disclosed in the present invention are phosphoramidite compounds, a preparation method therefor, and use thereof. The present invention provides phosphoramidite compounds represented by formula (1), wherein R is (I) or (II) and X is hydr...  
WO/2020/012332A1
Molecule having the structural formula (I): (I) for use as targeting probe of translating ribosomes and ribosome-interacting proteins.  
WO/2020/007070A1
The present invention discloses a crystal form, a preparation method and an application of a 4'-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic...  
WO/2020/002469A1
The present invention relates to new reagents and methods for modifying nucleic acids where an azide-containing nucleoside or nucleotide derivative is applied to living cells followed by a nitrogenous derivative of dibenzo-1,5-cyclooctad...  
WO/2020/001475A1
This invention relates to phosphorus-containing prodrugs of gemcitabine and their use in the treatment of cancer and viral infectious diseases. Compared with the parent drug (i.e., Gemcitabine), the prodrugs of present invention show a s...  
WO/2020/006157A1
Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of...  
WO/2019/246289A1
Methods, devices, reagents and kits designed to improve the performance of proteomic based assays are provided. Such methods have a wide utility in proteomic applications for research and development, diagnostics and therapeutics by prov...  
WO/2019/246403A1
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.  
WO/2019/237297A1
An improved process for preparing the compound (I) is provided: which may be used in the synthesis of e.g. AL-335; AL-355 is a nucleoside inhibitor of NS3B polymerase, which plays an important role in the replication of the hepatitis C v...  
WO/2019/236777A1
The invention provides methods of monitoring development of renal inflammation in a subject following administration of a nephrotoxic agent. The methods involve analyzing levels of one or more UDP-hexoses, such as UDP-glucose, UDP-galact...  
WO/2019/227526A1
Provided is a fluorescently labelled nucleotide having a structure represented by formula I. The fluorescently labelled nucleotide is linked by a covalent bond between deoxyribonucleoside triphosphate and a fluorescent dye molecule and i...  
WO/2019/228319A1
The present invention belongs to the field of medical technology and relates to an intestinal MCT1 carrier protein design-based prodrug and a preparation method therefor, and in particular relates to a preparation method for a short-chai...  
WO/2019/226952A1
An oligo- or polynucleotide analogue having one or more structures of the general formula: where B is a pyrimidine or purine nucleic acid base, or an analogue thereof, is used for treating obesity-related metabolic diseases.  
WO/2019/226755A1
The present invention relates to amino acid salts of nicotinic acid ribosides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein M1, R1, R2, and R3 are a...  
WO/2019/224172A1
The present invention relates to the manufacture of allofuranose from glucofuranose as defined in the description and in the claim. Allofuranos is an intermediate in the manufacture of oligonucleotides which can be used as a medicament.  
WO/2019/219070A1
The present invention belongs to the field of medicinal chemistry and relates to a deuterated oligonucleotide and a prodrug. In particular, the present invention relates to a compound represented by formula I or a pharmaceutically accept...  
WO/2019/219895A1
The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supp...  
WO/2019/221024A1
[Problem] To develop a purine base derivative. [Solution] A guanosine derivative compound characterized by being represented by the formula, wherein one of R1 and R2 is H and the other is any of H, OH, OCH3, and F, R3 is any of a compoun...  
WO/2019/222368A1
The present invention relates to amino acid salts of nicotinic acid mononucleotides and nicotinamide mononucleotides and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in...  
WO/2019/222500A1
Methods of modulating the activity of a cyclic dinucleotide (CDN) in a cell via membrane transporter are provided. Aspects of the methods may include contacting a cell with a CDN transporter-modulating agent to modulate transport of a CD...  
WO/2019/217470A1
Automated oligonucleotide synthesis-compatible sulforhodamine dye phosphoramidite compounds and labeled polynucleotides incorporating these dyes are provided.  
WO/2019/213756A1
Compounds are described which include polyvalent ligands linked to a cyclodextrin scaffold which exhibit strong binding affinities for lanthanides and favorable characteristics with respect to altering the relaxation time of coordinated ...  
WO/2019/211799A1
The present disclosure relates to 2'3'-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.  
WO/2019/204869A1
The present invention relates to improved prodrugs, and compositions thereof. In particular, it relates to amphiphilic gemcitabine prodrugs or amphiphilic prodrugs of other biologically active molecules with the capacity to make liquid c...  
WO/2019/209840A1
Provided herein are methods and compositions related to treating and/or preventing rheumatoid arthritis in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide ribosi...  
WO/2019/208571A1
The present invention provides: an amidite compound represented by formula (1), which enables synthesis of RNA with high purity; and a method for producing a polynucleotide, which uses this compound. (In the formula, R represents a group...  

Matches 501 - 550 out of 9,650